Highlights of weekly biotech stock moves

ALK-Abello A/S (CSE:ALK-B) gained DKK4 to DKK420.50 last week after it and partner Merck & Co. Inc. (NYSE:MRK) said FDA accepted for review a BLA from Merck for grass Allergy Immunotherapy Tablet (AIT). Merck said it expects a decision in 1Q14; the specific PDUFA date is not disclosed.

Cangene Corp. (TSX:CNJ) was up C$0.15 to C$2.90 last week after FDA approved a BLA for botulism antitoxin heptavalent (BAT) to treat patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The approval triggered an $18.5 million payment from HHS's Biomedical Advanced Research and Development Authority to Cangene, which developed the product under a 2006 contract with BARDA that is worth up to $423 million...